{"id":"dexamethasone-acetate","rwe":[{"pmid":"41532726","year":"2026","title":"Microenvironment-responsive hydrogels with drug-loaded microspheres for sustained dexamethasone acetate release and experimental autoimmune uveitis suppression.","finding":"","journal":"Journal of materials chemistry. B","studyType":"Clinical Study"},{"pmid":"40892535","year":"2026","title":"Synthesis and characterization of nanocapsules containing anti-inflammatory drugs: in vitro and in silico biological activity.","finding":"","journal":"Journal of toxicology and environmental health. Part A","studyType":"Clinical Study"},{"pmid":"40470782","year":"2025","title":"Severe tinea faciei mimicking favus-like lesions linked to rabbit exposure: A case report.","finding":"","journal":"The Journal of international medical research","studyType":"Clinical Study"},{"pmid":"40126618","year":"2025","title":"New intraocular lens containing a drug delivery system (IOL-DDS) loaded with dexamethasone.","finding":"","journal":"Biomedical microdevices","studyType":"Clinical Study"},{"pmid":"39931937","year":"2025","title":"Orally Administrated Precision Nanomedicine for Restoring the Intestinal Barrier and Alleviating Inflammation in Treatment of Inflammatory Bowel Disease.","finding":"","journal":"ACS applied materials & interfaces","studyType":"Clinical Study"}],"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glucocorticoid receptor","category":"target"},{"label":"NR3C1","category":"gene"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Multiple myeloma","category":"indication"},{"label":"Merck","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Antiemetics","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Hormonal","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Glucocorticoids","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":693.843,"date":"","count":373,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 373 times (LLR=694)"},{"llr":682.619,"date":"","count":289,"signal":"Neutrophil count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 289 times (LLR=683)"},{"llr":276.671,"date":"","count":125,"signal":"Lymphocyte count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 125 times (LLR=277)"},{"llr":272.215,"date":"","count":205,"signal":"White blood cell count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 205 times (LLR=272)"},{"llr":202.147,"date":"","count":255,"signal":"Anaemia","source":"DrugCentral FAERS","actionTaken":"Reported 255 times (LLR=202)"},{"llr":160.75,"date":"","count":70,"signal":"Fracture","source":"DrugCentral FAERS","actionTaken":"Reported 70 times (LLR=161)"},{"llr":146.946,"date":"","count":92,"signal":"Plasma cell myeloma","source":"DrugCentral FAERS","actionTaken":"Reported 92 times (LLR=147)"},{"llr":128.172,"date":"","count":63,"signal":"Dementia","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=128)"},{"llr":127.316,"date":"","count":261,"signal":"Pneumonia","source":"DrugCentral FAERS","actionTaken":"Reported 261 times (LLR=127)"},{"llr":97.808,"date":"","count":139,"signal":"Thrombocytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 139 times (LLR=98)"},{"llr":95.353,"date":"","count":49,"signal":"Tumour lysis syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=95)"},{"llr":92.337,"date":"","count":142,"signal":"Neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 142 times (LLR=92)"},{"llr":88.1,"date":"","count":55,"signal":"Myelosuppression","source":"DrugCentral FAERS","actionTaken":"Reported 55 times (LLR=88)"},{"llr":86.263,"date":"","count":61,"signal":"Bone marrow failure","source":"DrugCentral FAERS","actionTaken":"Reported 61 times (LLR=86)"},{"llr":86.04,"date":"","count":24,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=86)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Merck & Co.","patents":[{"type":"Method of Use","number":"10028965","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2034-05-23"},{"type":"Method of Use","number":"8563027","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2030-02-12"},{"type":"Method of Use","number":"12144889","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2041-04-26"},{"type":"Method of Use","number":"12150896","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2036-10-07"},{"type":"Formulation","number":"11097061","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2039-06-23"},{"type":"Method of Use","number":"10022502","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2034-06-22"},{"type":"Method of Use","number":"11458041","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2037-11-16"},{"type":"Formulation","number":"11304961","applicant":"DEXCEL PHARMA TECHNOLOGIES LTD","territory":"US","tradeName":"HEMADY","expiryDate":"2037-12-18"},{"type":"Formulation","number":"8409606","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2030-05-14"},{"type":"Formulation","number":"10799642","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2032-05-11"},{"type":"Formulation","number":"10159683","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2034-05-23"},{"type":"Formulation","number":"10537585","applicant":"DEXCEL PHARMA TECHNOLOGIES LTD","territory":"US","tradeName":"HEMADY","expiryDate":"2037-12-18"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$7.2702/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$2,617","description":"DEXAMETHASONE 0.1% EYE DROP","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DEXAMETHASONE ACETATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:27:15.487808+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:27:15.486872+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:27:22.336557+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DEXAMETHASONE ACETATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:27:23.221890+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL63565/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:27:24.611758+00:00"}},"allNames":"decadron-la","offLabel":[],"synonyms":["dexamethasone acetate","decadronal","neofordex"],"timeline":[{"date":"1973-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from MERCK to Merck"},{"date":"1973-09-06","type":"positive","source":"DrugCentral","milestone":"FDA approval (Merck)"}],"aiSummary":"Decadron-La (Dexamethasone Acetate) is a corticosteroid medication developed by Merck, targeting the glucocorticoid receptor. It is used to treat multiple myeloma and is classified as a small molecule modality. As an off-patent medication, it is available from generic manufacturers. Decadron-La is a commercial product with a long history of FDA approval since 1973. Its commercial status and availability make it a viable treatment option for patients.","approvals":[{"date":"1973-09-06","orphan":false,"company":"MERCK","regulator":"FDA"}],"brandName":"Decadron-La","ecosystem":[{"indication":"Multiple myeloma","otherDrugs":[{"name":"belantamab mafodotin","slug":"belantamab-mafodotin","company":"Glaxosmithkline"},{"name":"bortezomib","slug":"bortezomib","company":"Millennium Pharms"},{"name":"carfilzomib","slug":"carfilzomib","company":"Onyx Pharms"},{"name":"carmustine","slug":"carmustine","company":"Emcure Pharms Ltd"}],"globalPrevalence":176000}],"mechanism":{"target":"Glucocorticoid receptor","novelty":"Follow-on","targets":[{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"}],"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid","explanation":"","oneSentence":"","technicalDetail":"Decadron-La (Dexamethasone Acetate) is a synthetic glucocorticoid that exerts its effects by binding to the glucocorticoid receptor (GR), a transcription factor that regulates gene expression. This binding leads to the suppression of pro-inflammatory genes and the induction of anti-inflammatory genes, resulting in the reduction of inflammation and immune responses."},"commercial":{"launchDate":"1973","_launchSource":"DrugCentral (FDA 1973-09-06, MERCK)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/826","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DEXAMETHASONE%20ACETATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DEXAMETHASONE ACETATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:30:12.425180","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:27:26.523584+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"alclometasone dipropionate","drugSlug":"alclometasone-dipropionate","fdaApproval":"1982-12-14","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amcinonide","drugSlug":"amcinonide","fdaApproval":"1979-10-18","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"auranofin","drugSlug":"auranofin","fdaApproval":"1985-05-24","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"beclometasone dipropionate","drugSlug":"beclometasone-dipropionate","fdaApproval":"1976-05-12","relationship":"same-target"},{"drugName":"betamethasone","drugSlug":"betamethasone","fdaApproval":"1961-04-17","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"betamethasone acetate","drugSlug":"betamethasone-acetate","fdaApproval":"1965-03-03","relationship":"same-target"},{"drugName":"betamethasone benzoate","drugSlug":"betamethasone-benzoate","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"betamethasone dipropionate","drugSlug":"betamethasone-dipropionate","fdaApproval":"1975-01-29","patentExpiry":"Aug 31, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"betamethasone phosphate","drugSlug":"betamethasone-phosphate","fdaApproval":"1965-03-03","relationship":"same-target"},{"drugName":"betamethasone valerate","drugSlug":"betamethasone-valerate","fdaApproval":"1967-09-02","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"dexamethasone acetate","indications":{"approved":[{"name":"Multiple myeloma","source":"DrugCentral","snomedId":109989006,"regulator":"FDA","usPrevalence":35000,"globalPrevalence":176000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"}],"offLabel":[],"pipeline":[]},"currentOwner":"Merck","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"alclometasone-dipropionate","brandName":"alclometasone dipropionate","genericName":"alclometasone dipropionate","approvalYear":"1982","relationship":"same-target"},{"drugId":"amcinonide","brandName":"amcinonide","genericName":"amcinonide","approvalYear":"1979","relationship":"same-target"},{"drugId":"auranofin","brandName":"auranofin","genericName":"auranofin","approvalYear":"1985","relationship":"same-target"},{"drugId":"beclometasone-dipropionate","brandName":"beclometasone dipropionate","genericName":"beclometasone dipropionate","approvalYear":"1976","relationship":"same-target"},{"drugId":"betamethasone","brandName":"betamethasone","genericName":"betamethasone","approvalYear":"1961","relationship":"same-target"},{"drugId":"betamethasone-acetate","brandName":"betamethasone acetate","genericName":"betamethasone acetate","approvalYear":"1965","relationship":"same-target"},{"drugId":"betamethasone-benzoate","brandName":"betamethasone benzoate","genericName":"betamethasone benzoate","approvalYear":"","relationship":"same-target"},{"drugId":"betamethasone-dipropionate","brandName":"betamethasone dipropionate","genericName":"betamethasone dipropionate","approvalYear":"1975","relationship":"same-target"},{"drugId":"betamethasone-phosphate","brandName":"betamethasone phosphate","genericName":"betamethasone phosphate","approvalYear":"1965","relationship":"same-target"},{"drugId":"betamethasone-valerate","brandName":"betamethasone valerate","genericName":"betamethasone valerate","approvalYear":"1967","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":["Lymphoma"],"enrollment":129,"completionDate":"2026-12-31"},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT01553214","phase":"PHASE4","title":"Improving White Blood Cell Collection From Healthy Donors","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2012-12-31","conditions":["Allogeneic Granulocyte Donation"],"enrollment":1000,"completionDate":"2032-01-01"},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":["Triple Negative Breast Neoplasms"],"enrollment":1000,"completionDate":"2030-05-18"},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":["Breast Neoplasms","Triple Negative Breast Neoplasms","HR Low-Positive/HER2-Negative Breast Neoplasms"],"enrollment":2400,"completionDate":"2034-12-29"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT03798678","phase":"PHASE1","title":"CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-08","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":36,"completionDate":"2026-06-30"},{"nctId":"NCT06413498","phase":"PHASE3","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2024-08-23","conditions":["Multiple Myeloma"],"enrollment":450,"completionDate":"2031-07"},{"nctId":"NCT06182774","phase":"PHASE3","title":"Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-04-10","conditions":["Multiple Myeloma"],"enrollment":570,"completionDate":"2032-07-31"},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":["Multiple Myeloma"],"enrollment":70,"completionDate":"2026-09-30"},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":520,"completionDate":"2030-06-14"},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":["Acute Lymphoblastic Leukemia, Adult"],"enrollment":80,"completionDate":"2030-03-01"},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":["Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer"],"enrollment":770,"completionDate":"2032-11-09"},{"nctId":"NCT07463807","phase":"PHASE1,PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":162,"completionDate":"2026-08-31"},{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":["Leukemia, Acute Lymphoblastic"],"enrollment":6430,"completionDate":"2033-06"},{"nctId":"NCT07489521","phase":"PHASE4","title":"Arthrosemid vs. Steroid for the Management Knee Osteoarthritis","status":"RECRUITING","sponsor":"Cappagh National Orthopaedic Hospital","startDate":"2026-03","conditions":["Osteo Arthritis Knee","Osteoarthritis","Intraarticular Injection"],"enrollment":200,"completionDate":"2027-09"},{"nctId":"NCT07494136","phase":"PHASE4","title":"Dose Dependent Steroid Injections","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-05","conditions":["Lumbar Radiculopathy","Sciatica","Back Pain With Radiation"],"enrollment":150,"completionDate":"2027-05"},{"nctId":"NCT01846390","phase":"PHASE1","title":"Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2013-10-01","conditions":["Peripheral T-Cell Lymphoma","Diffuse Large B-Cell Lymphoma"],"enrollment":21,"completionDate":"2018-09-19"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":80,"completionDate":"2028-02-28"},{"nctId":"NCT04751175","phase":"PHASE4","title":"Management of Pain in Lumbar Arthrodesis","status":"COMPLETED","sponsor":"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta","startDate":"2013-07-04","conditions":["Pain, Postoperative"],"enrollment":128,"completionDate":"2025-12-31"},{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":["Multiple Myeloma"],"enrollment":944,"completionDate":"2027-05-31"},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":348,"completionDate":"2028-07-01"},{"nctId":"NCT05012033","phase":"","title":"Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2023-04-12","conditions":["Thyroid Eye Disease","Vasculitis","COPD Exacerbation Acute","Asthma","Inflammatory Disease"],"enrollment":120,"completionDate":"2030-12-31"},{"nctId":"NCT04847453","phase":"PHASE1","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-03","conditions":["Recurrent AL Amyloidosis","Refractory AL Amyloidosis"],"enrollment":24,"completionDate":"2026-06-30"},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT07497165","phase":"","title":"Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":["Relapsed/Refractory Multiple Myeloma (RRMM)","Multiple Myeloma"],"enrollment":48,"completionDate":"2027-06-30"},{"nctId":"NCT05675449","phase":"PHASE1","title":"A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-12-14","conditions":["Multiple Myeloma"],"enrollment":59,"completionDate":"2028-02-29"},{"nctId":"NCT07498998","phase":"NA","title":"Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-07-30","conditions":["Carpal Tunnel Syndrome (CTS)","Glucocorticoid","Pain","Dextrose"],"enrollment":105,"completionDate":"2026-08-30"},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":["Non Small Cell Lung Cancer"],"enrollment":780,"completionDate":"2034-10-23"},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":["Ovarian Neoplasms","Ovarian Cancer"],"enrollment":900,"completionDate":"2033-02-25"},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":["DS Stage I Multiple Myeloma","DS Stage II Multiple Myeloma","DS Stage III Multiple Myeloma"],"enrollment":525,"completionDate":"2026-09-18"},{"nctId":"NCT04835129","phase":"PHASE2","title":"Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2022-01-10","conditions":["Multiple Myeloma"],"enrollment":28,"completionDate":"2027-06-01"},{"nctId":"NCT06170788","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-15","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":614,"completionDate":"2030-05-27"},{"nctId":"NCT06863272","phase":"PHASE1,PHASE2","title":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-03","conditions":["Castration-Resistant Prostatic Cancer","Metastasis"],"enrollment":360,"completionDate":"2031-04-01"},{"nctId":"NCT04756726","phase":"PHASE1","title":"Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"C4 Therapeutics, Inc.","startDate":"2021-04-27","conditions":["Multiple Myeloma","Lymphoma, Non-Hodgkin's"],"enrollment":224,"completionDate":"2026-12-31"},{"nctId":"NCT06232044","phase":"PHASE1,PHASE2","title":"Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-04-23","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":88,"completionDate":"2030-08-01"},{"nctId":"NCT07404709","phase":"PHASE1,PHASE2","title":"Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2026-02-28","conditions":["Sudden Hearing Loss","Extracellular Vesicles"],"enrollment":9,"completionDate":"2028-12-31"},{"nctId":"NCT07493486","phase":"PHASE2","title":"IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-02-01","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)","Intrathecal Chemotherapy"],"enrollment":31,"completionDate":"2023-08-31"},{"nctId":"NCT06932562","phase":"PHASE3","title":"A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant","status":"RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2025-12-23","conditions":["Multiple Myeloma"],"enrollment":1000,"completionDate":"2036-12"},{"nctId":"NCT07452198","phase":"PHASE3","title":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2026-03-09","conditions":["Multiple Myeloma"],"enrollment":358,"completionDate":"2030-03"},{"nctId":"NCT07033039","phase":"NA","title":"Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre","status":"RECRUITING","sponsor":"University of Nove de Julho","startDate":"2026-01-30","conditions":["Rhinoplasty","Edema"],"enrollment":60,"completionDate":"2030-11-30"},{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)","Prostatic Neoplasms"],"enrollment":1314,"completionDate":"2030-12-02"},{"nctId":"NCT04933539","phase":"PHASE2","title":"Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-31","conditions":["Multiple Myeloma"],"enrollment":14,"completionDate":"2032-10-31"},{"nctId":"NCT07489872","phase":"NA","title":"Comparison of Intrathecal Morphine and Rectus Sheath Block for Postoperative Pain Management After Lower Abdominal Surgery With Midline Incision","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marmara University","startDate":"2025-02-24","conditions":["Postoperative Analgesia","Pain Management"],"enrollment":66,"completionDate":"2026-07-30"},{"nctId":"NCT07486544","phase":"PHASE3","title":"Soaked Pharyngeal Packing Agents in Septoplasty","status":"RECRUITING","sponsor":"Assiut University","startDate":"2026-03-20","conditions":["Sore Throat"],"enrollment":90,"completionDate":"2026-06-04"},{"nctId":"NCT06353386","phase":"PHASE1,PHASE2","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":["Prostatic Neoplasms, Castration-Resistant"],"enrollment":220,"completionDate":"2029-01-15"},{"nctId":"NCT06314334","phase":"PHASE2","title":"Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-04","conditions":["Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type"],"enrollment":210,"completionDate":"2028-12-30"},{"nctId":"NCT07095452","phase":"PHASE2,PHASE3","title":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-01-08","conditions":["Multiple Myeloma"],"enrollment":660,"completionDate":"2042-01"},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":["Multiple Myeloma"],"enrollment":310,"completionDate":"2027-02-01"},{"nctId":"NCT05519085","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Celgene","startDate":"2022-09-20","conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":810,"completionDate":"2033-11-30"},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":["Acute Lymphoblastic Leukemia","Immunotherapy","Blinatumomab","Inotuzumab Ozogamicin"],"enrollment":26,"completionDate":"2027-12-31"},{"nctId":"NCT06235567","phase":"PHASE1,PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":["Keratoconus"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT07479979","phase":"PHASE1,PHASE2","title":"Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Natalie Callander","startDate":"2026-07","conditions":["Relapse Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":62,"completionDate":"2029-07"},{"nctId":"NCT01297764","phase":"PHASE1,PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2011-04","conditions":["Multiple Myeloma"],"enrollment":17,"completionDate":"2026-07"},{"nctId":"NCT06152575","phase":"PHASE3","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-08","conditions":["Multiple Myeloma"],"enrollment":492,"completionDate":"2027-12-30"},{"nctId":"NCT02773030","phase":"PHASE1,PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":["Multiple Myeloma"],"enrollment":466,"completionDate":"2028-07-28"},{"nctId":"NCT06393374","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-24","conditions":["Triple-Negative Breast Cancer"],"enrollment":1530,"completionDate":"2037-12-14"},{"nctId":"NCT07227597","phase":"PHASE1,PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":["Small Cell Lung Cancer Extensive Stage"],"enrollment":170,"completionDate":"2030-12-30"},{"nctId":"NCT05319730","phase":"PHASE1,PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":230,"completionDate":"2029-04-10"},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":["Nausea","Vomiting","Drug-Related Side Effects and Adverse Reactions","Neoplasms"],"enrollment":204,"completionDate":"2026-09"},{"nctId":"NCT05623020","phase":"PHASE3","title":"A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-11-10","conditions":["Multiple Myeloma"],"enrollment":1116,"completionDate":"2033-10-03"},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":["Cervical Cancer"],"enrollment":1023,"completionDate":"2031-10-29"},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":["Prostate Cancer Metastatic"],"enrollment":1310,"completionDate":"2028-08-02"},{"nctId":"NCT05748171","phase":"PHASE2","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-17","conditions":["ACUTE LYMPHOBLASTIC LEUKEMIA"],"enrollment":100,"completionDate":"2036-11-04"},{"nctId":"NCT07485127","phase":"EARLY_PHASE1","title":"Comparison Between Dexamethasone and Dexmedetomidine in Spinal Anesthesia for Cases With Fracture Pelvis Fixation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sohag University","startDate":"2026-02-08","conditions":["Fracture Pelvis"],"enrollment":60,"completionDate":"2026-08-31"},{"nctId":"NCT02405676","phase":"PHASE2,PHASE3","title":"BNHL-2015 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2015-01-01","conditions":["Mature B-cell Non-Hodgkin Lymphoma"],"enrollment":200,"completionDate":"2029-12"},{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":["Pediatric Anaplastic Large Cell Lymphoma"],"enrollment":172,"completionDate":"2029-03-01"},{"nctId":"NCT04973605","phase":"PHASE1,PHASE2","title":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2021-09-16","conditions":["Relapsed/Refractory Multiple Myeloma"],"enrollment":246,"completionDate":"2026-11"},{"nctId":"NCT07222761","phase":"PHASE3","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-01-02","conditions":["Relapsed and/or Refractory Multiple Myeloma (RRMM)"],"enrollment":915,"completionDate":"2034-09-17"},{"nctId":"NCT04910568","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-07-26","conditions":["Multiple Myeloma"],"enrollment":126,"completionDate":"2029-12-10"},{"nctId":"NCT06136598","phase":"PHASE1","title":"A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-30","conditions":["Prostatic Neoplasms","Metastatic Castration-Resistant Prostate Cancer"],"enrollment":14,"completionDate":"2026-03-09"},{"nctId":"NCT07482891","phase":"PHASE4","title":"An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2026-03-10","conditions":["Chemotherapy-induced Nausea and Vomiting"],"enrollment":200,"completionDate":"2026-12-31"},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":["T-cell Lymphoblastic Lymphoma"],"enrollment":200,"completionDate":"2029-12-31"},{"nctId":"NCT03173092","phase":"PHASE4","title":"A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2017-11-13","conditions":["Multiple Myeloma"],"enrollment":141,"completionDate":"2026-11-30"},{"nctId":"NCT05083169","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-14","conditions":["Multiple Myeloma"],"enrollment":587,"completionDate":"2028-12-08"},{"nctId":"NCT02491632","phase":"PHASE2,PHASE3","title":"Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-13","conditions":["Advanced Malignant Neoplasm","Fatigue","Metastatic Malignant Neoplasm","Recurrent Malignant Neoplasm","Refractory Malignant Neoplasm"],"enrollment":90,"completionDate":"2026-12-31"},{"nctId":"NCT03301454","phase":"PHASE2","title":"Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2018-08-20","conditions":["Esophageal Cancer, Squamous Cell"],"enrollment":15,"completionDate":"2022-07-05"},{"nctId":"NCT07476235","phase":"","title":"Predictors of Treatment Response to Stellate Ganglion Block in Cervical Radicular Pain","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2024-10-08","conditions":["Radiculopathy, Cervical Region"],"enrollment":90,"completionDate":"2025-09-15"},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":["Clonal Cytopenia of Undetermined Significance","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Hodgkin Lymphoma","Recurrent Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Lymphoma","Chronic Myelomonocytic Leukemia"],"enrollment":80,"completionDate":"2033-11-02"},{"nctId":"NCT07480785","phase":"NA","title":"TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2026-01-16","conditions":["Uterine Fibroids (Leiomyoma)","Ovarian Tumors","Gallstones"],"enrollment":780,"completionDate":"2027-10-31"},{"nctId":"NCT05272826","phase":"PHASE2","title":"Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients","status":"RECRUITING","sponsor":"Canadian Myeloma Research Group","startDate":"2024-12-12","conditions":["Multiple Myeloma"],"enrollment":75,"completionDate":"2031-03"},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":["Lymphoblastic Lymphoma"],"enrollment":150,"completionDate":"2031-12"},{"nctId":"NCT06207123","phase":"PHASE1,PHASE2","title":"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-13","conditions":["Acute Leukemia","Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"enrollment":15,"completionDate":"2026-12-01"},{"nctId":"NCT07477587","phase":"PHASE1","title":"A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-05-27","conditions":["Multiple Myeloma (MM)"],"enrollment":258,"completionDate":"2028-02-22"},{"nctId":"NCT07434024","phase":"NA","title":"Erector Spinae Plane Block for Acute Low Back Pain","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-03","conditions":["Non-specific Low Back Pain (NSLBP)"],"enrollment":300,"completionDate":"2030-01"},{"nctId":"NCT06615479","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-03-12","conditions":["Relapsed or Refractory Multiple Myeloma (RRMM)"],"enrollment":440,"completionDate":"2032-06-22"},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":["Multiple Myeloma"],"enrollment":759,"completionDate":"2040-08"},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","Lymphoblastic Lymphoma"],"enrollment":53,"completionDate":"2029-03-30"},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":["Multiple Myeloma"],"enrollment":210,"completionDate":"2029-09-03"},{"nctId":"NCT06353022","phase":"PHASE2","title":"Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-06-26","conditions":["Multiple Myeloma"],"enrollment":103,"completionDate":"2030-06-26"},{"nctId":"NCT07478315","phase":"NA","title":"IMPOWER-QoL: IMPact Of Discontinuing Premedication for WEekly Paclitaxel on bReast Cancer Patient's Quality Of Life","status":"NOT_YET_RECRUITING","sponsor":"Charles LeMoyne Hospital","startDate":"2026-03-15","conditions":["Breast Cancer"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT05552976","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-01-10","conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":525,"completionDate":"2029-07-25"},{"nctId":"NCT04512235","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-11-03","conditions":["AL Amyloidosis"],"enrollment":281,"completionDate":"2027-04-08"},{"nctId":"NCT07224672","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-20","conditions":["Amyloidosis"],"enrollment":60,"completionDate":"2032-12-13"},{"nctId":"NCT04504825","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-08-25","conditions":["AL Amyloidosis"],"enrollment":125,"completionDate":"2027-10-22"},{"nctId":"NCT01615029","phase":"PHASE1,PHASE2","title":"Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-06-26","conditions":["Multiple Myeloma"],"enrollment":45,"completionDate":"2024-10-23"},{"nctId":"NCT05663866","phase":"PHASE2","title":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-05-18","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":68,"completionDate":"2026-07-30"},{"nctId":"NCT06789367","phase":"PHASE4","title":"The Effect of Dexamethasone Administration Route in PENG Block for Pediatric Hip Surgery","status":"COMPLETED","sponsor":"Poznan University of Medical Sciences","startDate":"2025-02-01","conditions":["Hip Dysplasia","Hip Disease"],"enrollment":60,"completionDate":"2026-03-03"},{"nctId":"NCT07474909","phase":"NA","title":"Perineural vs Intravenous Dexamethasone as an Adjuvant to Brachial Plexus Block in Pediatric Hand Surgery","status":"NOT_YET_RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2026-04-01","conditions":["Hand Injuries and Disorders","Wrist Sprain"],"enrollment":150,"completionDate":"2027-01-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000179099","MMSL":"4552","NDDF":"002174","UNII":"DWN2WN457X","VUID":"4017924","CHEBI":"CHEBI:4463","VANDF":"4017922","INN_ID":"816","RXNORM":"22690","UMLSCUI":"C0057598","chemblId":"CHEMBL63565","ChEMBL_ID":"CHEMBL1651","KEGG_DRUG":"D02174","DRUGBANK_ID":"DB14649","PDB_CHEM_ID":" DEX","PUBCHEM_CID":"236702","SNOMEDCT_US":"109070008","SECONDARY_CAS_RN":"55812-90-3","MESH_DESCRIPTOR_UI":"D003907","MESH_SUPPLEMENTAL_RECORD_UI":"C018038"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1973-","companyName":"Merck","relationship":"Original Developer"}],"publicationCount":221,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"originalDeveloper":"Merck","recentPublications":[{"date":"2026 Feb 4","pmid":"41532726","title":"Microenvironment-responsive hydrogels with drug-loaded microspheres for sustained dexamethasone acetate release and experimental autoimmune uveitis suppression.","journal":"Journal of materials chemistry. B"},{"date":"2026","pmid":"40892535","title":"Synthesis and characterization of nanocapsules containing anti-inflammatory drugs: in vitro and in silico biological activity.","journal":"Journal of toxicology and environmental health. Part A"},{"date":"2025 Jun","pmid":"40470782","title":"Severe tinea faciei mimicking favus-like lesions linked to rabbit exposure: A case report.","journal":"The Journal of international medical research"},{"date":"2025 Mar 24","pmid":"40126618","title":"New intraocular lens containing a drug delivery system (IOL-DDS) loaded with dexamethasone.","journal":"Biomedical microdevices"},{"date":"2025 Feb 19","pmid":"39931937","title":"Orally Administrated Precision Nanomedicine for Restoring the Intestinal Barrier and Alleviating Inflammation in Treatment of Inflammatory Bowel Disease.","journal":"ACS applied materials & interfaces"}],"companionDiagnostics":[],"genericManufacturers":2,"_genericFilersChecked":true,"genericManufacturerList":["Watson Labs","Watson Labs Teva"],"status":"approved","companyName":"Merck","companyId":"merck","modality":"Small molecule","firstApprovalDate":"1973","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1973-09-06T00:00:00.000Z","mah":"MERCK","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1973-09-06T00:00:00.000Z","mah":"MERCK","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1973-09-06T00:00:00.000Z","mah":"MERCK","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1973-09-06T00:00:00.000Z","mah":"MERCK","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1973-09-06T00:00:00.000Z","mah":"MERCK","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1973-09-06T00:00:00.000Z","mah":"MERCK","brand_name_local":null,"application_number":""},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8563027","territory":"US","patent_type":"Method of Use","expiry_date":"2030-02-12T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8409606","territory":"US","patent_type":"Formulation","expiry_date":"2030-05-14T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10799642","territory":"US","patent_type":"Formulation","expiry_date":"2032-05-11T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10028965","territory":"US","patent_type":"Method of Use","expiry_date":"2034-05-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10159683","territory":"US","patent_type":"Formulation","expiry_date":"2034-05-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10022502","territory":"US","patent_type":"Method of Use","expiry_date":"2034-06-22T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12150896","territory":"US","patent_type":"Method of Use","expiry_date":"2036-10-07T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11458041","territory":"US","patent_type":"Method of Use","expiry_date":"2037-11-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11304961","territory":"US","patent_type":"Formulation","expiry_date":"2037-12-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10537585","territory":"US","patent_type":"Formulation","expiry_date":"2037-12-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11097061","territory":"US","patent_type":"Formulation","expiry_date":"2039-06-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12144889","territory":"US","patent_type":"Method of Use","expiry_date":"2041-04-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:27:26.523584+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}